CU06-1004 clinical trials
Also written SAC-1004.
How each study uses CU06-1004 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CU06-1004 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
Who runs them
Industry 3 · Other 0
Curacle Co., Ltd. (3)
Studies
Open first, then newest update. How each study uses CU06-1004 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of CU06-1004 in Patients With Daibetic Macular EdemaNot yet recruitingPhase 2Curacle Co., Ltd.NCT07459829Written as CU06-1004
- The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)CompletedPhase 2Curacle Co., Ltd.NCT05573100Written as CU06-1004
- First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy VolunteersCompletedPhase 1Curacle Co., Ltd.NCT04795037Written as CU06-1004, Single dose